Tag: HD-MAP
Vaxxas hits enrollment target in trial of HD-MAP technology for pandemic response
Australian biotechnology company Vaxxas has completed enrollment for its largest clinical trial to date, testing the safety and immune response of its high-density microarray patch (HD-MAP) for vaccine delivery.
Vaxxas unveils positive clinical trial results for needle-free COVID-19 vaccine
Australia biotechnology company Vaxxas said it achieved positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate.
Vaxxas kickstarts needle-free COVID-19 vaccine clinical trial
Australian biotechnology company Vaxxas has begun the Phase I clinical trial of the first needle-free COVID-19 vaccine candidate.
Vaxxas receives $8.2 million Commonwealth Government grant to support manufacturing scale-up in its Australian...
Media Release by Vaxxas
Vaxxas will receive an AU$8.2 million second-round grant as part of the Commonwealth Government’s Modern Manufacturing Initiative (MMI) to support the...
Construction commences of Australia’s first needle-free vaccine manufacturing facility
Vaxxas, a Queensland biotechnology business, has begun construction on a new facility in Northshore Hamilton, Brisbane to develop and manufacture its needle-free vaccination technology.
The...
Featured Article
Delivering growth: how invoice finance transformed a logistics business
For a smaller freight-forwarding company to compete with international behemoths, Global Trade Logistics founder Gary Coutsoudis knows he and his team must outperform.
